M&A Deal Summary |
|
|---|---|
| Date | 2015-04-13 |
| Target | CAPP Medical |
| Sector | Medical Products |
| Buyer(s) | Roche |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1896 |
| Sector | Life Science |
| Employees | 100,920 |
| Revenue | 62.4B CHF (2024) |
Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. It offers diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 24 of 44 |
| Sector: Medical Products M&A | 4 of 5 |
| Type: Add-on Acquisition M&A Deals | 22 of 36 |
| State: California M&A | 7 of 16 |
| Country: United States M&A | 13 of 30 |
| Year: 2015 M&A | 2 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-01-16 |
Trophos SA
Marseille, France Trophos is a late stage clinical stage company with a pipeline of original molecules in development for neurological and cardiac diseases. These diseases include spinal muscular atrophy (SMA), Multiple Sclerosis (MS) disability progression and Cardiac Ischemia-Reperfusion Injury (IRI). Trophos additionally has collaborative research projects in other neurological conditions. |
Buy | €470M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-08-13 |
GeneWeave BioSciences
Los Gatos, California, United States GeneWeave BioSciences, Inc. is a privately-held in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions to aid healthcare providers in the fight against drug-resistant bacteria by enabling impactful surveillance programs, early therapy guidance and successful antibiotic stewardship. |
Buy | $425M |